戻る Agenda
From Faster Regulatory Approval to Actual Patient Access: What Could be Done to Increase Certainty around Clinical Benefit and Predictability of Decision Making?
Session Chair(s)
Claudine Sapède, PHARMD
Director, Global HTA Policy
NOVARTIS INTERNATIONAL, Switzerland
Compelling value demonstration is critical in securing patient access to new treatment options today and in the future and even more so for products potentially undergoing accelerated pathways. On the basis of case studies, panellists will present new approaches that could be explored and will highlight what they see as opportunities and important learning.
Speaker(s)
Bridging Clinical Trials to the Real World at Times of Launch – A Case Study in Alzheimer’s Disease
Michael Happich, PHD
Eli Lilly, Germany
HTA director
A Case Study in Addressing Comparative Effectiveness Evidence Gaps in Personalised Medicine
Jessica Davies, MPH
AstraZeneca, United Kingdom
Senior Director, Real World Evidence